Abstract:Four novel diosmetin derivatives showed strong multifunctional anti‐AD activities, especially 3 showed the strongest inhibitory activities on ChE and Aβ1‐42 aggregations. Furthermore, 3 also showed good BBB permeability, in vivo ROS scavenging activity and low cytotoxicity, which indicated that 3 might be a promising lead compound for the development of new multifunctional anti‐AD ligand. With the increasing aging population, rational design of drugs for Alzheimer's disease (AD) treatment has become an important research area. Based on the multifunctional design strategy, four diosmetin derivatives (1–4) were designed, synthesized, and characterized by 1H NMR, 13C NMR, and MS. Docking study was firstly applied to substantiate the design strategies and then the biological activities including cholinesterase inhibition, metal chelation, antioxidation and β‐amyloid (Aβ) aggregation inhibition in vitro were evaluated. The results showed that 1–4 had good acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition, metal chelation (selective chelation of Cu2+ ions), antioxidation, self‐induced, Cu2+‐induced, and AChE‐induced Aβ aggregation inhibition activities, and suitable blood–brain barrier (BBB) permeability. Especially, compound 3 had the strongest inhibitory effect on AChE (10−8 M magnitude) and BuChE (10−7 M magnitude) and showed the best inhibition on AChE‐induced Aβ aggregation with 66.14% inhibition ratio. Furthermore, compound 3 could also reduce intracellular reactive oxygen species (ROS) levels in Caenorhabditis elegans and had lower cytotoxicity. In summary, 3 might be considered as a potential multifunctional anti‐AD ligand.

Diosmetin derivatives as multifunctional anti‐AD ligands: Design, synthesis, and biological evaluation